Abstract:Acquired tamoxifen (TAM) resistance limits the therapeutic benefit of TAM in patients with hormone-dependent breast cancer. The switch from estrogen-dependent to growth factor-dependent growth is a critical step in this process. However, the molecular mechanisms underlying this switch remain poorly understood. In this study, we established a TAM resistant cell sub line (MCF-7/TAM) from estrogen receptor-α (ER-α66) positive breast cancer MCF-7 cells by culturing ER-α66-positive MCF-7 cells in medium plus 1 μM TAM over 6 months. MCF-7/TAM cells were then found to exhibit accelerated proliferation rate together with enhanced in vitro migratory and invasive ability. And the estrogen receptor-α36 (ER-α36), a novel 36-kDa variant of ER-α66, was dramatically overexpressed in this in vitro model, compared to the parental MCF-7 cells. Meanwhile, the expression of epidermal growth factor receptor (EGFR) in MCF-7/TAM cells was significantly up-regulated both in mRNA level and protein level, and the expression of ER-α66 was greatly down-regulated oppositely. In the subsequent studies, we overexpressed ER-α36 in MCF-7 cells by stable transfection and found that ER-α36 transfected MCF-7 cells (MCF-7/ER-α36) similarly exhibited decreased sensitivity to TAM, accelerated proliferative rate and enhanced in vitro migratory and invasive ability, compared to empty vector transfected MCF-7 cells (MCF-7/V). Real-time qPCR and Western blotting analysis revealed that MCF-7/ER-α36 cells possessed increased EGFR expression but decreased ER-α66 expression both in mRNA level and protein level, compared to MCF-7/V cells. This change in MCF-7/ER-α36 cells could be reversed by neutralizing anti-ER-α36 antibody treatment. Furthermore, knock-down of ER-α36 expression in MCF-7/TAM cells resulted in reduced proliferation rate together with decreased in vitro migratory and invasive ability. Decreased EGFR mRNA and protein expression as well as increased ER-α66 mRNA expression were also observed in MCF-7/TAM cells with down-regulated ER-α36 expression. In addition, blocking EGFR/ERK signaling in MCF-7/ER-α36 cells could restore the expression of ER-α66 partly, suggesting a regulatory function of EGFR/ERK signaling in down-regulation of ER-α66 expression. In conclusion, our results indicated for the first time a regulatory role of ER-α36 in up-regulation of EGFR expression and down-regulation of ER-α66 expression, which could be an underlying mechanism for the growth status switch in breast tumors that contribute to the generation of acquired TAM resistance. And ER-α36 could be considered a potential new therapeutic target in breast tumors which have acquired resistance to TAM.

Tip30 Deletion in Mmtv-Neu Mice Leads to Enhanced Egfr Signaling and Development of Estrogen Receptor-Positive and Progesterone Receptor-Negative Mammary Tumors

Tip30 Controls Differentiation of Murine Mammary Luminal Progenitor to Estrogen Receptor-Positive Luminal Cell Through Regulating FoxA1 Expression.

Deletion of Tip30 Leads to Rapid Immortalization of Murine Mammary Epithelial Cells and Ductal Hyperplasia in the Mammary Gland

Loss of Estrogen-Regulated MIR135A1 at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer

TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice

Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer

Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.

Tip30 Interacts with an Estrogen Receptor Alpha-Interacting Coactivator Cia and Regulates C-Myc Transcription

P53 Genotype As a Determinant of ER Expression and Tamoxifen Response in the MMTV-Wnt-1 Model of Mammary Carcinogenesis.

Ebag9 Inducing Hyporesponsiveness Of T Cells Promotes Tumor Growth And Metastasis In 4t1 Murine Mammary Carcinoma

TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin

Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles

BRCA1-associated Mammary Tumorigenesis is Dependent on Estrogen Rather Than Progesterone Signaling

Caloric Restriction Inhibits Mammary Tumorigenesis in MMTV-ErbB2 Transgenic Mice Through the Suppression of ER and ErbB2 Pathways and Inhibition of Epithelial Cell Stemness in Premalignant Mammary Tissues

Tip30 Deficiency Increases Susceptibility To Tumorigenesis

Nuclear Estrogen Receptor-Mediated Notch Signaling and GPR30-mediated PI3K/AKT Signaling in the Regulation of Endometrial Cancer Cell Proliferation.

Effect of the p-Estrogen Receptor at Serine on Its Function and Breast Growth

Conditional Loss of PTEN Leads to Precocious Development and Neoplasia in the Mammary Gland.

Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

Conserved Genetic Networks Define Er-Alpha Status And Luminal And Basal Phenotypes In Mouse And Human Mammary Cancer: Added Value From The Mouse

Ventral prostate and mammary gland phenotype in mice with complete deletion of the ERβ gene